{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:07:00Z","timestamp":1792598820730,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"DOI":"10.1007\/s11547-025-01961-9","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T08:32:36Z","timestamp":1739349156000},"page":"422-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Baseline 18F-FDG PET\/CT for predicting pathological response to neoadjuvant chemotherapy and prognosis in locally advanced breast cancer patients: analysis of tumor and lymphoid organs metabolic parameters"],"prefix":"10.1007","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1715-9953","authenticated-orcid":false,"given":"Silvia","family":"Taralli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia Clara","family":"Pafundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Tempesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Di Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Pontolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Scardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia","family":"Calcagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"12","key":"1961_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH et al (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475\u20131495","journal-title":"Ann Oncol"},{"key":"1961_CR2","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 1.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"1961_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.20.25223","volume":"217","author":"DC Teichgraeber","year":"2021","unstructured":"Teichgraeber DC, Guirguis MS, Whitman GJ (2021) Breast cancer staging: updates in the AJCC cancer staging manual, 8th ed., and current challenges for radiologists, from the AJR special series on cancer staging. AJR 217:278\u2013290","journal-title":"AJR"},{"key":"1961_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164\u2013172","journal-title":"Lancet"},{"issue":"10","key":"1961_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/bjs.5894","volume":"94","author":"JS Mieog","year":"2007","unstructured":"Mieog JS, van der Hage JA, van de Velde CJ (2007) Neoadjuvant chemotherapy for operable breast cancer. Br J Surg 94(10):1189\u20131200","journal-title":"Br J Surg"},{"issue":"2","key":"1961_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2214\/AJR.19.21177","volume":"213","author":"GA Ulaner","year":"2019","unstructured":"Ulaner GA (2019) PET\/CT for patients with breast cancer: Where is the clinical impact? AJR 213(2):254\u2013265","journal-title":"AJR"},{"issue":"5","key":"1961_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00259-015-3295-z","volume":"43","author":"D Groheux","year":"2016","unstructured":"Groheux D, Mankoff D, Espi\u00e9 M et al (2016) 18F-FDG PET\/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. Eur J Nucl Med Mol Imaging 43(5):983\u2013993","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"1961_CR8","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.3390\/cancers15102715","volume":"15","author":"N Quartuccio","year":"2023","unstructured":"Quartuccio N, Alongi P, Urso L et al (2023) 18F-FDG PET-derived volume-based parameters to predict disease-free survival in patients with grade III breast cancer of different molecular subtypes candidates to neoadjuvant chemotherapy. Cancers (Basel) 15(10):2715. https:\/\/doi.org\/10.3390\/cancers15102715","journal-title":"Cancers (Basel)"},{"key":"1961_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.critrevonc.2017.02.014","volume":"112","author":"MA Lindenberg","year":"2017","unstructured":"Lindenberg MA, Miquel-Cases A, Ret\u00e8l VP, Sonke GS et al (2017) Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: a systematic literature review. Crit Rev Oncol Hematol 112:198\u2013207","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1961_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11307-018-1181-3","volume":"21","author":"K Paydary","year":"2019","unstructured":"Paydary K, Seraj SM, Zadeh MZ et al (2019) The evolving role of FDG-PET\/CT in the diagnosis, staging, and treatment of breast cancer. Mol Imaging Biol 21(1):1\u201310","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"1961_CR11","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2967\/jnumed.118.210922","volume":"59","author":"D Groheux","year":"2018","unstructured":"Groheux D (2018) Now is the time to use 18F-FDG PET\/CT to optimize neoadjuvant treatment in triple-negative breast cancer! J Nucl Med 59(6):863\u2013864","journal-title":"J Nucl Med"},{"issue":"1","key":"1961_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13058-020-01350-2","volume":"22","author":"S Han","year":"2020","unstructured":"Han S, Choi JY (2020) Prognostic value of 18F-FDG PET and PET\/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 22(1):119. https:\/\/doi.org\/10.1186\/s13058-020-01350-2","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1961_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1148\/radiol.2015141638","volume":"277","author":"D Groheux","year":"2015","unstructured":"Groheux D, Majdoub M, Sanna A et al (2015) Early metabolic response to neoadjuvant treatment: FDG PET\/CT criteria according to breast cancer subtype. Radiology 277(2):358\u2013371","journal-title":"Radiology"},{"issue":"7","key":"1961_CR14","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2967\/jnumed.117.203075","volume":"59","author":"O Humbert","year":"2018","unstructured":"Humbert O, Lasserre M, Bertaut A et al (2018) Breast cancer blood flow and metabolism on dual-acquisition 18F-FDG PET: correlation with tumor phenotype and neoadjuvant chemotherapy response. J Nucl Med 59(7):1035\u20131041","journal-title":"J Nucl Med"},{"issue":"1","key":"1961_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1186\/s12885-020-07505-w","volume":"20","author":"IH Lee","year":"2020","unstructured":"Lee IH, Lee SJ, Lee J et al (2020) Utility of 18F-FDG PET\/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer 20(1):1106. https:\/\/doi.org\/10.1186\/s12885-020-07505-w","journal-title":"BMC Cancer"},{"issue":"3","key":"1961_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/MNM.0000000000001332","volume":"42","author":"N Akdeniz","year":"2021","unstructured":"Akdeniz N, K\u00f6mek H, K\u00fc\u00e7\u00fck\u00f6ner M et al (2021) The role of basal 18F-FDG PET\/CT maximum standard uptake value and maximum standard uptake change in predicting pathological response in breast cancer patients receiving neoadjuvant chemotherapy. Nucl Med Commun 42(3):315\u2013324","journal-title":"Nucl Med Commun"},{"issue":"23","key":"1961_CR17","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.3390\/cancers14235869","volume":"14","author":"L Urso","year":"2022","unstructured":"Urso L, Evangelista L, Alongi P et al (2022) The value of semiquantitative parameters derived from 18F-FDG PET\/CT for predicting response to neoadjuvant chemotherapy in a cohort of patients with different molecular subtypes of breast cancer. Cancers (Basel) 14(23):5869. https:\/\/doi.org\/10.3390\/cancers14235869","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1961_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.2967\/jnumed.115.154138","volume":"56","author":"D Groheux","year":"2015","unstructured":"Groheux D, Sanna A, Majdoub M et al (2015) Baseline tumor 18F-FDG uptake and modifications after 2 cycles of neoadjuvant chemotherapy are prognostic of outcome in ER+\/HER2- breast cancer. J Nucl Med 56(6):824\u2013831","journal-title":"J Nucl Med"},{"issue":"3","key":"1961_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s00259-013-2616-3","volume":"41","author":"O Humbert","year":"2014","unstructured":"Humbert O, Berriolo-Riedinger A, Cochet A et al (2014) Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging 41(3):416\u2013427","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1961_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13058-016-0793-2","volume":"19","author":"D Groheux","year":"2017","unstructured":"Groheux D, Martineau A, Teixeira L et al (2017) 18FDG-PET\/CT for predicting the outcome in ER+\/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. Breast Cancer Res 19(1):3. https:\/\/doi.org\/10.1186\/s13058-016-0793-2","journal-title":"Breast Cancer Res"},{"issue":"23","key":"1961_CR21","doi-asserted-by":"publisher","first-page":"10363","DOI":"10.7314\/APJCP.2014.15.23.10363","volume":"15","author":"G Ozyalvacli","year":"2014","unstructured":"Ozyalvacli G, Yesil C, Kargi E et al (2014) Diagnostic and prognostic importance of the neutrophil lymphocyte ratio in breast cancer. Asian Pac J Cancer Prev 15(23):10363\u201310366","journal-title":"Asian Pac J Cancer Prev"},{"key":"1961_CR22","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.12659\/MSM.906709","volume":"23","author":"H Sun","year":"2017","unstructured":"Sun H, Yin CQ, Liu Q et al (2017) Clinical significance of routine blood test-associated inflammatory index in breast cancer patients. Med Sci Monit 23:5090\u20135095","journal-title":"Med Sci Monit"},{"issue":"2","key":"1961_CR23","doi-asserted-by":"publisher","first-page":"925","DOI":"10.7150\/thno.35989","volume":"10","author":"J Schwenck","year":"2020","unstructured":"Schwenck J, Sch\u00f6rg B, Fiz F et al (2020) Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET. Theranostics 10(2):925\u2013937","journal-title":"Theranostics"},{"issue":"11","key":"1961_CR24","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1007\/s00259-021-05322-2","volume":"48","author":"RD Seban","year":"2021","unstructured":"Seban RD, Rouzier R, Latouche A et al (2021) Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET\/CT as independent prognostic biomarkers of recurrence in resected breast cancer. Eur J Nucl Med Mol Imaging 48(11):3560\u20133570","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1961_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3390\/jimaging8110297","volume":"8","author":"F Tustumi","year":"2022","unstructured":"Tustumi F, Albenda DG, Perrotta FS et al (2022) Prognostic value of bone marrow uptake using 18F-FDG PET\/CT scans in solid neoplasms. J Imaging 8(11):297. https:\/\/doi.org\/10.3390\/jimaging8110297","journal-title":"J Imaging"},{"issue":"12","key":"1961_CR26","doi-asserted-by":"publisher","first-page":"e0208861","DOI":"10.1371\/journal.pone.0208861","volume":"13","author":"JI Bang","year":"2018","unstructured":"Bang JI, Yoon HJ, Kim BS (2018) Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET\/CT for prediction of tumor recurrence in breast cancer. PLoS ONE 13(12):e0208861. https:\/\/doi.org\/10.1371\/journal.pone.0208861","journal-title":"PLoS ONE"},{"issue":"8","key":"1961_CR27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 30(8):1194\u20131220","journal-title":"Ann Oncol"},{"issue":"9","key":"1961_CR28","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24(9):2206\u20132223","journal-title":"Ann Oncol"},{"key":"1961_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1961_CR30","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1007\/s00259-015-3128-0","volume":"42","author":"E Quak","year":"2015","unstructured":"Quak E, Le Roux PY, Hofman MS et al (2015) Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. Eur J Nucl Med Mol Imaging 42:2072\u20132082","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1961_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40336-023-00584-2","volume":"11","author":"D Groheux","year":"2023","unstructured":"Groheux D, Ulaner GA, Hindie E (2023) Breast cancer: treatment response assessment with FDG-PET\/CT in the neoadjuvant and in the metastatic setting. Clin Transl Imaging 11:439\u2013452","journal-title":"Clin Transl Imaging"},{"issue":"7","key":"1961_CR32","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano AE, Edge SB, Hortobagyi GN (2018) Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol 25(7):1783\u20131785","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"1961_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","volume":"5","author":"O Yersal","year":"2014","unstructured":"Yersal O, Barutca S (2014) Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol 5(3):412\u2013424","journal-title":"World J Clin Oncol"},{"issue":"1","key":"1961_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5603\/NMR.2021.0004","volume":"24","author":"I Sarikaya","year":"2021","unstructured":"Sarikaya I (2021) Breast cancer and PET imaging. Nucl Med Rev Cent East Eur 24(1):16\u201326","journal-title":"Nucl Med Rev Cent East Eur"},{"issue":"3","key":"1961_CR35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","volume":"38","author":"D Groheux","year":"2011","unstructured":"Groheux D, Giacchetti S, Moretti JL et al (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38(3):426\u2013435","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1961_CR36","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.clbc.2012.09.010","volume":"13","author":"DW Kim","year":"2013","unstructured":"Kim DW, Kim CG (2013) Effects of DNA ploidy and S-phase fraction on fluorine-18 FDG uptake of primary breast cancer lesions. Clin Breast Cancer 13(3):196\u2013201","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"1961_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.clbc.2017.09.006","volume":"18","author":"E Akimoto","year":"2018","unstructured":"Akimoto E, Kadoya T, Kajitani K et al (2018) Role of 18F-PET\/CT in predicting prognosis of patients with breast cancer after neoadjuvant chemotherapy. Clin Breast Cancer 18(1):45\u201352","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"1961_CR38","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.breast.2012.12.020","volume":"22","author":"BB Koolen","year":"2013","unstructured":"Koolen BB, Pengel KE, Wesseling J et al (2013) FDG PET\/CT during neoadjuvant chemotherapy may predict response in ER-positive\/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast 22(5):691\u2013697","journal-title":"Breast"},{"issue":"5","key":"1961_CR39","first-page":"290","volume":"38","author":"MJ Tello Gal\u00e1n","year":"2019","unstructured":"Tello Gal\u00e1n MJ, Garc\u00eda Vicente AM, P\u00e9rez Beteta J et al (2019) Global heterogeneity assessed with 18F-FDG PET\/CT. Relation with biological variables and prognosis in locally advanced breast cancer. Rev Esp Med Nucl Imagen Mol 38(5):290\u2013297","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"issue":"3","key":"1961_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2967\/jnumed.112.108837","volume":"54","author":"M Hatt","year":"2013","unstructured":"Hatt M, Groheux D, Martineau A et al (2013) Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54(3):341\u2013349","journal-title":"J Nucl Med"},{"issue":"2","key":"1961_CR41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4274\/mirt.galenos.2022.44154","volume":"31","author":"G Tatar","year":"2022","unstructured":"Tatar G, \u00d6zkul \u00d6, Al\u00e7in G (2022) The value of 18F-FDG PET\/CT imaging in the evaluation of interim neoadjuvant chemotherapy response in locally advanced breast cancer. Mol Imaging Radionucl Ther 31(2):123\u2013129","journal-title":"Mol Imaging Radionucl Ther"},{"key":"1961_CR42","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2967\/jnumed.106.035774","volume":"48","author":"M Soret","year":"2007","unstructured":"Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48:932\u2013945","journal-title":"J Nucl Med"},{"issue":"1","key":"1961_CR43","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13550-020-00660-y","volume":"10","author":"JW Lee","year":"2020","unstructured":"Lee JW, Kim SY, Han SW et al (2020) [18F]FDG uptake of bone marrow on PET\/CT for predicting distant recurrence in breast cancer patients after surgical resection. EJNMMI Res 10(1):72. https:\/\/doi.org\/10.1186\/s13550-020-00660-y","journal-title":"EJNMMI Res"},{"issue":"8","key":"1961_CR44","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/MNM.0000000000001227","volume":"41","author":"K Pak","year":"2020","unstructured":"Pak K, Seok JW, Kim HY et al (2020) Prognostic value of metabolic tumor volume and total lesion glycolysis in breast cancer: a meta-analysis. Nucl Med Commun 41(8):824\u2013829","journal-title":"Nucl Med Commun"},{"key":"1961_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.breast.2016.08.003","volume":"30","author":"T Higuchi","year":"2016","unstructured":"Higuchi T, Nishimukai A, Ozawa H et al (2016) Prognostic significance of preoperative 18F-FDG PET\/CT for breast cancer subtypes. Breast 30:5\u201312","journal-title":"Breast"},{"issue":"2","key":"1961_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1200\/JCO.2002.20.2.379","volume":"20","author":"R Bos","year":"2002","unstructured":"Bos R, van der Hoeven JJM, van der Wall E et al (2002) Biologic correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20(2):379\u2013387","journal-title":"J Clin Oncol"},{"issue":"10","key":"1961_CR47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s11547-017-0779-x","volume":"122","author":"E \u015eahin","year":"2017","unstructured":"\u015eahin E, Elbo\u011fa U (2017) Relationship between reticuloendothelial systems\u2019 FDG uptake level and clinicopathological features in patient with invasive ductal breast cancer. Radiol Med 122(10):785\u2013792","journal-title":"Radiol Med"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-01961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-025-01961-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-025-01961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:27:25Z","timestamp":1741750045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-025-01961-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1961"],"URL":"https:\/\/doi.org\/10.1007\/s11547-025-01961-9","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"13 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was performed in accordance with the principles of the 1964 Helsinki declaration and approved by the local ethics committee (ID 6754).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}